Glycoproteomics-based Liquid-biopsy LDT Development Service for Non Small Cell Lung Carcinoma (NSCLC)

Glycoproteomics-based Liquid-biopsy for NSCLC

NSCLC is the most common type of lung cancer, which accounts for approximately 85% of all lung cancer cases. Glycosylation, as a post-translational modification (PTM) of proteins, has garnered significant attention due to its crucial role in diverse physiological processes and tumor development. Altered glycosylation patterns have been frequently observed on the cell surface and secreted proteins in lung cancer cells. Thus specific glycosylation patterns of proteins can serve as important biomarkers. Glycoproteomics-based liquid biopsy offers a non-invasive and highly informative method to identify and characterize glycosylation changes in cancer.

Glycoproteomics-based Liquid-biopsy LDT Development for NSCLC at Creative Biolabs

For glycoproteomic analysis of NSCLC samples, Creative Biolabs has established a robust and cutting-edge liquid-biopsy LDT platform with advanced techniques for the enrichment and analysis of glycopeptides to provide comprehensive information about glycan composition, branching patterns, glycosylation sites, and relative quantitation.

Fig.1 LDT development for N-glycosylation profiling in NSCLC samples.

Technologies for Glycoproteomics-based LDT Development at Creative Biolabs

• By tailoring our approaches to specific needs, we adeptly select the most suitable method to enrich either targeted glycopeptides or global glycopeptides.
• Additionally, we utilize multiple reaction monitoring (MRM) mass spectrometry for further validation of targeted proteins or peptides. MRM facilitates elevated specificity, enabling precise quantification with heightened sensitivity.

Fig.2 Technologies utilized for LDT development.

Advantages

Fig.3 Advantages of our LDT development.

Published Data

Technology: Glycoproteomic analysis

Journal: British Journal of Cancer

Published: 2016

Results: Serum AACT especially GlcNAcylated AACT can serve as a good early biomarker for NSCLC detection and improve the clinical diagnostic efficiency of CEA.

Fig.4 Diagnostic performance of GlcNAcylated AACT and CEA.¹

Experienced scientists at Creative Biolabs are excited to leverage our specialized expertise to assist researchers worldwide in their pioneering projects focused on glycoproteomics-based liquid biopsy in NSCLC. Our offerings include top-notch custom services, tailored to accommodate our clients' specific requirements. To obtain more information, please feel free to contact us or submit an inquiry directly.

Reference

1. Jin, Yanxia, et al. "Identification of GlcNAcylated alpha-1-antichymotrypsin as an early biomarker in human non-small-cell lung cancer by quantitative proteomic analysis with two lectins." British journal of cancer 114.5 (2016): 532-544.

Related Services:

1. NASH
2. Pancreas Carcinoma
3. Renal Cell Carcinoma
4. Nasopharyngeal Carcinoma
5. HCC
6. Advanced Adenoma
7. Colorectal Cancer
8. Prostate Cancer